Apolipoprotein assays: standardization and quality control.

A correct approach to standardization, accuracy-based methods, and well-defined quality assurance programs is indispensable for the definition of international reference intervals of apo A-I and apo B. Variability in the immunochemical determination of apo A-I and apo B can be due to both preanalytical and analytical variations, and standardized laboratories should evaluate and minimize each source of error in determining the reference intervals. A key requirement to reduce the variation between measurement techniques is the use of a common protocol for the calibration of the different methods. The basis of a calibration system is the primary standard with the absolute mass accurately determined. The primary standard is indispensable in assigning an accurate target value to reference materials with a reference method in which the primary standard immunochemically reacts the same as the protein in plasma. The reference material, which must behave immunochemically the same as the patient's sample in all methods, is then used to assign a target value to the calibrator in each method and system. Following this procedure, all assay results can be traced back to the primary standard via the serum reference material. The development and distribution of reference and quality control materials, which do not exhibit matrix effects between methods, is fundamental for the standardization process.

[1]  J. Deslypere,et al.  Discriminative value of lipids and apoproteins in coronary heart disease. , 1982, Atherosclerosis.

[2]  R. Krauss,et al.  Modulation of apolipoprotein B antigenic determinants in human low density lipoprotein subclasses. , 1985, The Journal of biological chemistry.

[3]  S. Marcovina,et al.  Standardization of the Immunochemical Determination of Apolipoproteins A-I and B: A Report on the International Federation of Clinical Chemistry Meeting on Standardization of Apolipoprotein A-I and B Measurements (Basis for Future Consensus), Vienna, Austria, April 18-19, 1989 , 1989 .

[4]  Y. Marcel,et al.  Expression of human apolipoprotein A-I epitopes in high density lipoproteins and in serum. , 1987, Journal of lipid research.

[5]  W. Hazzard,et al.  Radioimmunoassay of human plasma Lp(a) lipoprotein. , 1977, Journal of lipid research.

[6]  W. Riesen,et al.  Apoproteins and lipids as discriminators of severity of coronary heart disease. , 1980, Atherosclerosis.

[7]  E Marth,et al.  Lipoprotein Lp(a) and the risk for myocardial infarction. , 1981, Atherosclerosis.

[8]  A. Sniderman,et al.  Apoproteins B and A-I and coronary artery disease in humans. , 1984, Arteriosclerosis.

[9]  B. Tsao,et al.  Immunochemical heterogeneity of human plasma apolipoprotein B. II. Expression of apolipoprotein B epitopes on native lipoproteins. , 1982, The Journal of biological chemistry.

[10]  S. Marcovina,et al.  Standardization of apolipoprotein B and A-I measurements. , 1989, Clinical chemistry.

[11]  C. Vassanelli,et al.  Evaluation of apolipoproteins A-I and B as markers of angiographically assessed coronary artery disease , 1988, La Ricerca in clinica e in laboratorio.

[12]  J. Brunzell,et al.  Apoprotein measurements and their clinical application. , 1989, Clinics in laboratory medicine.